Scott Howell

Former chief strategy officer, Novartis Pharmaceuticals Corporation

Articles by Scott Howell

Payers Believe Lowering Drug Prices While Improving Patient Access Is Possible—but There’s a Catch

ByScott Howell,Keith Bratti,Jeremy Bahr,Spencer Morrison

August 3rd 2022

Value-based price for access (VBPA) may increase access of specialty drugs for patients.

Latest Updated Articles

Trending on PharmExec

EMA Panel Backs Lilly’s Foundayo for Obesity and Type 2 Diabetes in Europe

FDA Approves Enspryng (Satralizumab) for Thyroid Eye Disease

The Bubble You Don’t Know You’re In: A Three-Part Series on The Medical Benefit Bubble

Domestic Manufacturing Is a Meaningful But Incomplete Answer

The Unique Considerations Mid-Sized Pharma Companies Face When Making MFN Deals